<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2019.97133</article-id><article-id pub-id-type="publisher-id">ACM-31388</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20190700000_43483458.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  宫颈癌早期筛查及检测新策略
  New Strategies for Early Screening and Detection of Cervical Cancer
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>苗</surname><given-names>雄伟</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>赵</surname><given-names>红</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>延安大学附属医院，陕西 延安</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>07</month><year>2019</year></pub-date><volume>09</volume><issue>07</issue><fpage>867</fpage><lpage>870</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    在过去的几十年里，美国在基于人群的广泛筛查发现，宫颈癌发病率和死亡率的显著下降。尽管取得了这样的筛查结果，但据估计2018年有13,240名美国女性被诊断出宫颈癌，并有4170人死于宫颈癌。大量一致的证据表明，感染高危型人乳头瘤病毒(hrHPV)是宫颈癌的病原体。这些感染很常见，发生在大多数性生活活跃的女性一生中。虽然大多数感染在几年的时间内都没有临床后果，但持续性感染可导致高级别宫颈癌前病变(如宫颈上皮内瘤变[CIN] 2级和3级)，并可发展为宫颈癌。大约30%的CIN 3级病变在30年内进展为侵袭性癌症。这种缓慢的进展为这些病变的发现和治疗提供了许多机会，从而破坏了癌症的发展轨迹。本篇综述着重讨论宫颈癌的早期筛查以及检测的新策略。
    Over the past few decades, extensive population-based screening in the United States has found significant declines in cervical cancer incidence and mortality. Despite the screening results, an estimated 13,240 US women were diagnosed with cervical cancer in 2018 and 4170 died of it. There is a large body of consistent evidence that human papillomavirus (hrHPV) infection is the causative agent of cervical cancer. These infections are common and occur in the lifetime of most sexually active women. Although most infections have no clinical consequences over a period of several years, persistent infections can lead to high-grade precancerous lesions (such as cervical intraepithelial neoplasia [CIN 2 and CIN 3]) that can progress to cervical cancer. About 30% of CIN III lesions develop into invasive cancers within 30 years. This slow progression offers many opportunities for discovery and treatment of these lesions, thus disrupting the cancer’s trajectory. This review focuses on the early screening of cervical cancer and new strategies for detection. 
  
 
</p></abstract><kwd-group><kwd>广泛筛查，细胞学检测，hrHPV检测，宫颈癌, Extensive Screening</kwd><kwd> Cytological Test</kwd><kwd> hrHPV Test</kwd><kwd> Cervical Cancer</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>宫颈癌早期筛查及检测新策略<sup> </sup></title><p>苗雄伟，赵红</p><p>延安大学附属医院，陕西 延安</p><p><img src="//html.hanspub.org/file/9-1570986x1_hanspub.png" /></p><p>收稿日期：2019年7月2日；录用日期：2019年7月17日；发布日期：2019年7月24日</p><disp-formula id="hanspub.31388-formula47"><graphic xlink:href="//html.hanspub.org/file/9-1570986x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>在过去的几十年里，美国在基于人群的广泛筛查发现，宫颈癌发病率和死亡率的显著下降。尽管取得了这样的筛查结果，但据估计2018年有13,240名美国女性被诊断出宫颈癌，并有4170人死于宫颈癌。大量一致的证据表明，感染高危型人乳头瘤病毒(hrHPV)是宫颈癌的病原体。这些感染很常见，发生在大多数性生活活跃的女性一生中 [<xref ref-type="bibr" rid="hanspub.31388-ref2">2</xref>] 。虽然大多数感染在几年的时间内都没有临床后果，但持续性感染可导致高级别宫颈癌前病变(如宫颈上皮内瘤变[CIN] 2级和3级)，并可发展为宫颈癌。大约30%的CIN 3级病变在30年内进展为侵袭性癌症。这种缓慢的进展为这些病变的发现和治疗提供了许多机会，从而破坏了癌症的发展轨迹。本篇综述着重讨论宫颈癌的早期筛查以及检测的新策略。</p><p>关键词 :广泛筛查，细胞学检测，hrHPV检测，宫颈癌</p><disp-formula id="hanspub.31388-formula48"><graphic xlink:href="//html.hanspub.org/file/9-1570986x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2019 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/9-1570986x7_hanspub.png" /> <img src="//html.hanspub.org/file/9-1570986x8_hanspub.png" /></p><p>在过去的几十年里，美国在基于人群的广泛筛查发现，宫颈癌发病率和死亡率的显著下降。尽管取得了这样的筛查结果，但据美国癌症协会估计仅在2017年就预测了12,820例新病例和4120例死亡病例 [<xref ref-type="bibr" rid="hanspub.31388-ref1">1</xref>] 。</p><p>大量一致的证据表明，感染高危型人乳头瘤病毒(hrHPV)是宫颈癌的病原体。这些感染很常见，发生在大多数性生活活跃的女性一生中 [<xref ref-type="bibr" rid="hanspub.31388-ref2">2</xref>] 。虽然大多数感染在几年的时间内都没有临床后果，但持续性感染可导致高级别宫颈癌前病变(如宫颈上皮内瘤变[CIN] 2级和3级)，并可发展为宫颈癌。大约30%的CIN 3级病变在30年内进展为侵袭性癌症 [<xref ref-type="bibr" rid="hanspub.31388-ref2">2</xref>] 。这种缓慢的进展为这些病变的发现和治疗提供了许多机会，从而破坏了癌症的发展轨迹。</p><p>2018年，美国预防服务工作组(USPSTF)更新了筛查指南 [<xref ref-type="bibr" rid="hanspub.31388-ref3">3</xref>] 。除了继续推荐年龄在21到29岁女性进行每三年细胞学检测(巴氏测试)之外，继续推行一个年龄30岁到65岁的高危人乳头状瘤病毒类型女性5年一次的检测，强制要求的检测策略是每5年对年龄在30到65岁的女性进行hrHPV测试。USPSTF表示，将所有检测结果异常的女性直接纳入阴道镜检查将导致阴道镜检查数量大大增加，但不建议对检测结果为hrHPV阳性的女性采用任何特定的分类策略；妇科肿瘤学会建议用HPV基因分型(HPV 16型或HPV 18型检测)对这些女性进行分类 [<xref ref-type="bibr" rid="hanspub.31388-ref4">4</xref>] 。</p><p>来自USPSTF、美国妇产科学院(ACOG) [<xref ref-type="bibr" rid="hanspub.31388-ref5">5</xref>] 和美国癌症协会(ACS)及其合作伙伴 [<xref ref-type="bibr" rid="hanspub.31388-ref6">6</xref>] 的现行筛查指南适用于平均患病风险的妇女(未预先诊断为高级别癌前病变或宫颈癌，免疫功能不受损的妇女，以及未在子宫内接触二乙烯雌酚的妇女)。还包括对高危妇女的扩大筛查建议 [<xref ref-type="bibr" rid="hanspub.31388-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.31388-ref7">7</xref>] 。此外，研究小组还建议，在进行过子宫颈切除子宫切除术的平均风险女性中，不要继续进行筛查。第三阶段的的认证策略扩展了筛选选项，并适应多种临床环境。2018年USPSTF推荐 [<xref ref-type="bibr" rid="hanspub.31388-ref3">3</xref>] 表明30岁至65岁的女性应该和她们的医疗人源讨论哪种测试策略最适合她们，建议她们在选择一种特定的策略时，可能要把自己的偏好作为重要考虑因素。USPSTF总结了单独选择hrHPV检测或联合检测而不是细胞学策略的临床意义如下：在一生的筛查中，基于hrHPV的策略将避免每1000名接受细胞学检查的EDC患者中约有1例额外的癌症病例，这表明在寿命方面取得了非常小的改善；然而，与单纯的细胞学相比，基于hrhpv的策略将使妇女接受更多的检测和程序 [<xref ref-type="bibr" rid="hanspub.31388-ref8">8</xref>] 。</p><p>共享决策很容易调用，但是实现起来很困难 [<xref ref-type="bibr" rid="hanspub.31388-ref9">9</xref>] 。解释较长的筛查间隔和较高的由于监测而进行更多检测的可能性之间的权衡可能是复杂和费时的，同时要将患者偏好纳入临床检测的考虑因素也是必要的。然而，许多女性可能不愿意参与如此细致入微的讨论，她们会征求临床医生的意见，看哪种策略能最好地平衡利弊。虽然USPSTF在其审议中没有考虑成本，但它指出，根据其对这一平衡的评估，细胞学或hrHPV检测单独优于联合检测。对于社会和卫生保健部门而言，最近的成本效益分析表明，每三年对年龄在21岁到29岁女性进行细胞学检测，可换为每5年对年龄30岁到65岁的低成本hrHPV测试，从利益，损害，费用的角度看更为合理平衡 [<xref ref-type="bibr" rid="hanspub.31388-ref10">10</xref>] 。</p><p>从卫生系统的角度来看，hrHPV初级筛查选项要求至少有一种已被美国食品和药物管理局批准用于该适应症的检测。对正常检测结果的跟踪是另一个可能决定哪些策略对系统工作效率最可行的因素。如果使用所有三种筛选策略，复杂性可能对负责协调后续访问和确保高质量服务的系统提出挑战。</p><p>除了筛查，临床医生还可以通过推荐适当的HPV疫苗接种来进一步实现宫颈癌预防的目标。建议9至14岁开始接种疫苗的女童和男童采用2剂接种计划；建议15至26岁开始接种该系列疫苗的人以及免疫功能低下的人服用3剂。在出现关于接种疫苗对人群影响的更多证据之前，所有指导小组都建议，接种疫苗的妇女应与未接种疫苗的妇女一样接受筛查。</p><p>宫颈癌预防领域是一个高度动态的领域，随着新证据的出现，临床医生应该期待临床指南的额外变化。然而，在对参与筛查项目的妇女的新战略充满热情之际，临床医生应该意识到，筛查对宫颈癌发病率和死亡率最深远的影响可以通过为未经筛查和筛查不足的妇女提供容易获得的低成本筛查、诊断检测和治疗来实现。一项新策略的出现单独测试了自我抽样的可能性，这一策略可能比随机抽样更有效，更能被女性接受。在指导小组推荐这种筛查方法之前，临床医生会进一步检查宫颈癌预防的目标，确认和筛查高危女性的做法，并为没有接受常规护理的女性提供治疗方案。</p></sec><sec id="s3"><title>文章引用</title><p>苗雄伟,赵 红. 宫颈癌早期筛查及检测新策略New Strategies for Early Screening and Detection of Cervical Cancer[J]. 临床医学进展, 2019, 09(07): 867-870. https://doi.org/10.12677/ACM.2019.97133</p></sec><sec id="s4"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.31388-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">American Cancer Society. Facts and Figures, 2017.  
&lt;br&gt;https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2017/cancer-facts-and-figures-2017.pdf</mixed-citation></ref><ref id="hanspub.31388-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Agency for Healthcare Research and Quality (2017) Evidence Synthesis No.158: Screening for Cervical Cancer with High-Risk Human Papillomavirus Testing: A Systematic Evidence Review for the US Preventive Services Task Force.  
&lt;br&gt;https://www.uspreventiveservicestaskforce.org/Home/GetFileByID/3279</mixed-citation></ref><ref id="hanspub.31388-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Curry, S.J., Krist, A.H., Owens, D.K., et al. (2018) Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement. JAMA: The Journal of the American Medical Association, 320, 674-686.  
&lt;br&gt;https://doi.org/10.1001/jama.2018.10897</mixed-citation></ref><ref id="hanspub.31388-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Huh, W.K., Ault, K.A., Chelmow, D., et al. (2015) Use of Primary High-Risk Human Papillomavirus Testing for Cervical Cancer Screening: Interim Clinical Guidance. Obstetrics &amp; Gynecology, 125, 330-337. 
&lt;br&gt;https://doi.org/10.1097/AOG.0000000000000669</mixed-citation></ref><ref id="hanspub.31388-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">(2016) Practice Bulletin No.168 Summary: Cervical Cancer Screening and Prevention. Obstetrics &amp; Gynecology, 128, 923-925. &lt;br&gt;https://doi.org/10.1097/AOG.0000000000001699</mixed-citation></ref><ref id="hanspub.31388-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Saslow, D., Solomon, D., Lawson, H.W., et al. (2012) American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of cervical Cancer. CA: A Cancer Journal for Clinicians, 62, 147-172.  
&lt;br&gt;https://doi.org/10.3322/caac.21139</mixed-citation></ref><ref id="hanspub.31388-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents (2019) Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. &lt;br&gt;https://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</mixed-citation></ref><ref id="hanspub.31388-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Massad, L.S., Einstein, M.H., Huh, W.K., et al. (2013) 2012 Updated Consensus Guidelines for the Management of Abnormal Cervical Cancer Screening Tests and Cancer Precursors. Obstetrics &amp; Gynecology, 121, 829-846.  
&lt;br&gt;https://doi.org/10.1097/AOG.0b013e3182883a34</mixed-citation></ref><ref id="hanspub.31388-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Kuppermann, M. and Sawaya, G.F. (2015) Shared Deci-sion-Making: Easy to Evoke, Challenging to Implement. JAMA Internal Medicine, 175, 167-168. &lt;br&gt;https://doi.org/10.1001/jamainternmed.2014.4606</mixed-citation></ref><ref id="hanspub.31388-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Sawaya, G.F., Sansted, E., Alarid-Escudero, F., et al. (2019) Estimated Quality of Life and Economic Outcomes Associated with 12 Cervical Cancer Screening Strategies: A Cost-Effectiveness Analysis. JAMA Internal Medicine, 179, 867-878.</mixed-citation></ref></ref-list></back></article>